AU2001278117A1 - Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen - Google Patents
Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigenInfo
- Publication number
- AU2001278117A1 AU2001278117A1 AU2001278117A AU7811701A AU2001278117A1 AU 2001278117 A1 AU2001278117 A1 AU 2001278117A1 AU 2001278117 A AU2001278117 A AU 2001278117A AU 7811701 A AU7811701 A AU 7811701A AU 2001278117 A1 AU2001278117 A1 AU 2001278117A1
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- endoplasmic reticulum
- chaperone polypeptide
- reticulum chaperone
- molecular vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010006519 Molecular Chaperones Proteins 0.000 title 1
- 108010008038 Synthetic Vaccines Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22290200P | 2000-08-03 | 2000-08-03 | |
US60/222,902 | 2000-08-03 | ||
PCT/US2001/024134 WO2002012281A2 (en) | 2000-08-03 | 2001-08-02 | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001278117A1 true AU2001278117A1 (en) | 2002-02-18 |
Family
ID=22834209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001278117A Abandoned AU2001278117A1 (en) | 2000-08-03 | 2001-08-02 | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
Country Status (8)
Country | Link |
---|---|
US (3) | US7342002B2 (en) |
EP (1) | EP1363938B1 (en) |
JP (2) | JP5087201B2 (en) |
AU (1) | AU2001278117A1 (en) |
CA (1) | CA2417214C (en) |
DK (1) | DK1363938T3 (en) |
ES (1) | ES2454640T3 (en) |
WO (1) | WO2002012281A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
US8128922B2 (en) * | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
AU2001290520A1 (en) * | 2000-08-01 | 2002-02-13 | The Johns Hokpins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
CA2417214C (en) | 2000-08-03 | 2016-06-21 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
EP1363660A4 (en) | 2001-02-01 | 2006-06-21 | Univ Johns Hopkins | Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation |
EP1621555A4 (en) * | 2003-04-18 | 2006-08-02 | Sekisui Chemical Co Ltd | Immunogen, composition for immunological use, and method of producing antibody using the same |
EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
CN103074316B (en) | 2003-05-22 | 2015-10-21 | 美国弗劳恩霍夫股份有限公司 | For expressing, transmitting and the recombinant carrier molecule of purification of target polypeptides |
WO2005081716A2 (en) * | 2003-11-24 | 2005-09-09 | The Johns Hopkins University | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) |
US20090028874A1 (en) * | 2003-12-24 | 2009-01-29 | Leiden University Medical Center | Synthetic Protein as Tumor-Specific Vaccine |
WO2006041157A1 (en) | 2004-10-15 | 2006-04-20 | Sekisui Chemical Co., Ltd. | Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody |
AU2005322960A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines |
EP1846026A4 (en) * | 2005-01-26 | 2008-07-02 | Univ Johns Hopkins | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
CN101378781B (en) * | 2005-08-03 | 2013-08-07 | 美国弗劳恩霍夫股份有限公司 | Compositions and methods for production of immunoglobulins |
EP1984388B1 (en) * | 2006-02-13 | 2016-07-06 | iBio, Inc. | Hpv antigens, vaccine compositions, and related methods |
US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
WO2008024844A2 (en) * | 2006-08-22 | 2008-02-28 | The Johns Hopkins University | Anticancer combination therapies |
WO2008046251A1 (en) * | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Fusion proteins containing n domain of human calreticulin and human papillomavirus type 16 e6 or e7 and uses thereof |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
US20100291683A1 (en) * | 2007-03-27 | 2010-11-18 | Lung-Ji Chang | Modified Antigen Presenting Cells and Methods of Use |
US8404252B2 (en) * | 2007-07-11 | 2013-03-26 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
WO2009095796A2 (en) * | 2008-01-28 | 2009-08-06 | The University Of British Columbia | Tapasin augmentation for enhanced immune response |
CN102014937A (en) | 2008-03-03 | 2011-04-13 | 迈阿密大学 | Allogeneic cancer cell-based immunotherapy |
EP2274001A4 (en) | 2008-03-20 | 2012-08-01 | Univ Miami | Heat shock protein gp96 vaccination and methods of using same |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
CA2736498C (en) * | 2008-09-11 | 2017-05-23 | Calretex, Llc | Compositions and methods for purifying calreticulin |
WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
CA2776144C (en) | 2009-09-29 | 2020-10-27 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
SI2591114T1 (en) * | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Immunisation of large mammals with low doses of rna |
AU2012220592A1 (en) * | 2011-02-23 | 2013-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Service | Combined cell based GP96-IG-SIV/HIV, recombinant GP120 protein vaccination for protection from SIV/HIV |
SI3473267T1 (en) | 2011-05-24 | 2022-01-31 | BioNTech SE | Individualized vaccines for cancer |
JP5981921B2 (en) * | 2011-09-02 | 2016-08-31 | 株式会社カネカ | Transgenic birds expressing foreign genes using the endoplasmic reticulum chaperone promoter |
WO2013093629A2 (en) * | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
EP3417874A1 (en) | 2012-11-28 | 2018-12-26 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
WO2014164727A1 (en) * | 2013-03-12 | 2014-10-09 | Wisconsin Alumni Research Foundation | A method of treating fungal infection |
WO2017155981A1 (en) * | 2016-03-07 | 2017-09-14 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
BR112019028280A2 (en) | 2017-07-04 | 2020-07-14 | Curevac Ag | nucleic acid molecules |
CN109182339A (en) * | 2018-09-06 | 2019-01-11 | 青岛农业大学 | A kind of flat Rockfish calprotectin gene of Xu Shi and application |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744133A (en) * | 1986-08-13 | 1998-04-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor |
US4898730A (en) * | 1987-03-13 | 1990-02-06 | The University Of British Columbia | Method to stimulate the immune response to specific antigens |
US5582831A (en) * | 1991-11-26 | 1996-12-10 | Yeda Research And Development Co., Ltd. | Anti-tumor vaccines |
EP0419569B1 (en) | 1988-06-15 | 1995-09-06 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
DE3907721A1 (en) * | 1989-03-10 | 1990-09-20 | Behringwerke Ag | IMMUNOGENIC REGIONS ON THE E7 PROTEIN OF THE HUMAN PAPILLOMVIERUS TYPE 16 |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5348945A (en) * | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
US5821088A (en) * | 1990-05-11 | 1998-10-13 | Siga Pharmaceuticals, Inc. | Use of gram-positive bacteria to express recombinant proteins |
AU8762991A (en) | 1990-09-26 | 1992-04-15 | Bristol-Myers Squibb Company | Human papilloma viral protein expression for use in vaccine compositions |
US5674486A (en) * | 1991-06-25 | 1997-10-07 | San Diego Regional Cancer Center | Cancer immunotherapy with carrier cells |
PT523391E (en) * | 1991-07-13 | 2003-08-29 | Dade Behring Marburg Gmbh | USING THE PEPTIDES DERIVED FROM THE HPV-16 E6 AND E7 GENES FOR DIAGNOSTIC PURPOSES |
GB9207701D0 (en) | 1992-04-08 | 1992-05-27 | Cancer Res Campaign Tech | Papillomavirus e7 protein |
IL106760A (en) | 1992-08-25 | 1999-12-31 | Miles Inc | Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus |
US5618536A (en) | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US5997869A (en) * | 1993-03-15 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens |
GB9306731D0 (en) * | 1993-03-31 | 1993-05-26 | Cancer Res Campaign Tech | Vaccines |
US5426097A (en) * | 1993-04-06 | 1995-06-20 | The Trustees Of Columbia University In The City Of New York | Calreticulin: a novel antithrombotic agent |
PT700445E (en) | 1993-06-04 | 2002-07-31 | Whitehead Biomedical Inst | STRESS PROTEINS AND THEIR USES |
US5646008A (en) | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
US5591716A (en) * | 1993-11-19 | 1997-01-07 | New York University | Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins |
EP0659438A1 (en) | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
US5854202A (en) | 1995-01-24 | 1998-12-29 | Dedhar; Shoukat | Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same |
AU5512096A (en) | 1995-05-17 | 1996-11-29 | University Of Alberta | Method of inhibiting restenosis using calreticulin |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
AU6504596A (en) | 1995-07-21 | 1997-02-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
AU724399B2 (en) | 1995-08-18 | 2000-09-21 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
DE19534348C2 (en) | 1995-09-15 | 1997-07-10 | Wieland Heinrich Prof Dr Med | Method for the determination of autoimmune phenomena |
US5824309A (en) * | 1995-12-05 | 1998-10-20 | University Of Massachusetts | Recombinant gas vesicles and uses thereof |
BR9708387A (en) * | 1996-03-28 | 2000-01-04 | Genitrix Llc | Process for vaccination of a mammal to a selected antigen, host and pathogenic cells, vaccine composition, nucleic acid, and engineered opsonin. |
EP0900380B1 (en) | 1996-04-26 | 2003-07-09 | Rijksuniversiteit te Leiden | Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes |
US5951975A (en) * | 1996-06-28 | 1999-09-14 | University Of Pittsburgh | Induction of CTLs specific for natural antigens by cross priming immunization |
IN183280B (en) * | 1996-09-20 | 1999-10-30 | Univ New Mexico | |
US5962318A (en) * | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
PT941315E (en) | 1996-11-26 | 2006-06-30 | Stressgen Biotechnologies Corp | STRESS PROTEINS CONTAINING FUSEO PROTEINS TO INDUCE IMMUNE RESPONSE |
US6046158A (en) * | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
WO1998048003A1 (en) | 1997-04-23 | 1998-10-29 | Shriners Hospital For Children | Calreticulin-deficient cells |
US6319503B1 (en) | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
KR20060111731A (en) * | 1997-08-05 | 2006-10-27 | 스트레스젠 바이오테크놀러지스 코포레이션 | Immune responses against hpv(human papillomavirus) antigens elicited by compositions comprising a fusion protein comprising an hpv antigen and a stress protein |
US6007821A (en) * | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US6331388B1 (en) * | 1997-10-17 | 2001-12-18 | Wisconsin Alumni Research Foundation | Immune response enhancer |
US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
AU4078599A (en) | 1998-05-13 | 1999-11-29 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
AU753249B2 (en) * | 1998-06-17 | 2002-10-10 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and methods of use thereof |
EP1728865A1 (en) * | 1998-09-04 | 2006-12-06 | Aventis Pasteur Limited | Treatment of cervical cancer |
US7001995B1 (en) * | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
CN1411512A (en) | 1999-10-20 | 2003-04-16 | 约翰霍普金斯大学医学院 | Chimeric immunogenic compositions and nucleir acids encoding them |
US6734173B1 (en) * | 1999-10-20 | 2004-05-11 | Johns Hopkins University | HSP DNA vaccines |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US20010034042A1 (en) * | 2000-01-20 | 2001-10-25 | Srivastava Pramod K. | Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
US6967075B2 (en) * | 2000-04-07 | 2005-11-22 | Schering Corporation | HCV replicase complexes |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
WO2002000242A2 (en) | 2000-06-26 | 2002-01-03 | Stressgen Biotechnologies Corporation | Human papilloma virus treatment |
AU2001290520A1 (en) | 2000-08-01 | 2002-02-13 | The Johns Hokpins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
CA2417214C (en) | 2000-08-03 | 2016-06-21 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
JP3930243B2 (en) * | 2000-11-06 | 2007-06-13 | 本田技研工業株式会社 | Magnet pump |
KR100909681B1 (en) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | RNA interference mediating small RNA molecules |
US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
EP1363660A4 (en) | 2001-02-01 | 2006-06-21 | Univ Johns Hopkins | Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation |
AU2002306736A1 (en) | 2001-03-16 | 2002-10-03 | Johns Hopkins University | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same |
US20030144221A1 (en) | 2001-07-17 | 2003-07-31 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL2-associated X protein expression |
EP1417353A4 (en) * | 2001-07-20 | 2005-08-03 | Univ Texas | Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin |
US20060040262A1 (en) | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
AU2003224732A1 (en) | 2002-03-25 | 2003-10-13 | The Trustees Of Boston University | Method of using anti-apoptotic factors in gene expression |
ES2391451T3 (en) | 2002-10-03 | 2012-11-26 | Wyeth Holdings Corporation | Fusion peptides comprising the E7 and E6 polypeptides of human papillomavirus and immunogenic compositions thereof. |
WO2005047501A1 (en) | 2003-02-24 | 2005-05-26 | Johns Hopkins University | Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins |
EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
WO2005081716A2 (en) | 2003-11-24 | 2005-09-09 | The Johns Hopkins University | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) |
AU2005322960A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines |
EP1846026A4 (en) | 2005-01-26 | 2008-07-02 | Univ Johns Hopkins | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
-
2001
- 2001-08-02 CA CA2417214A patent/CA2417214C/en not_active Expired - Lifetime
- 2001-08-02 WO PCT/US2001/024134 patent/WO2002012281A2/en active Application Filing
- 2001-08-02 ES ES01956081.2T patent/ES2454640T3/en not_active Expired - Lifetime
- 2001-08-02 DK DK01956081.2T patent/DK1363938T3/en active
- 2001-08-02 US US10/343,448 patent/US7342002B2/en not_active Expired - Lifetime
- 2001-08-02 JP JP2002518253A patent/JP5087201B2/en not_active Expired - Lifetime
- 2001-08-02 AU AU2001278117A patent/AU2001278117A1/en not_active Abandoned
- 2001-08-02 EP EP01956081.2A patent/EP1363938B1/en not_active Expired - Lifetime
-
2008
- 2008-01-15 US US12/014,541 patent/US8007781B2/en not_active Expired - Fee Related
- 2008-07-31 JP JP2008197856A patent/JP2009017883A/en active Pending
-
2012
- 2012-05-03 US US13/463,250 patent/US20130203961A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090148471A1 (en) | 2009-06-11 |
US20050054820A1 (en) | 2005-03-10 |
WO2002012281A9 (en) | 2003-03-06 |
JP5087201B2 (en) | 2012-12-05 |
CA2417214C (en) | 2016-06-21 |
US8007781B2 (en) | 2011-08-30 |
US7342002B2 (en) | 2008-03-11 |
EP1363938B1 (en) | 2013-12-11 |
DK1363938T3 (en) | 2014-03-24 |
EP1363938A2 (en) | 2003-11-26 |
US20130203961A1 (en) | 2013-08-08 |
JP2009017883A (en) | 2009-01-29 |
ES2454640T3 (en) | 2014-04-11 |
CA2417214A1 (en) | 2002-02-14 |
JP2004527213A (en) | 2004-09-09 |
WO2002012281A2 (en) | 2002-02-14 |
WO2002012281A3 (en) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001278117A1 (en) | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen | |
AU2001290520A1 (en) | Intercellular transport protein linked to an antigen as a molecular vaccine | |
AU2002309706A1 (en) | Novel meningitis conjugate vaccine | |
AU2001252458A1 (en) | Molecular antigen arrays and vaccines | |
AU2001276737A1 (en) | Protein injection preparations | |
AU2002353378A1 (en) | Vaccine for periodontal disease | |
AU2001273164A1 (en) | Membrane associated protein zupari | |
AU1951201A (en) | Peptide antigens | |
AU6086300A (en) | Recombinant envelope vaccine against flavivirus infection | |
AU2003230795A1 (en) | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen | |
AU2002254558A1 (en) | Novel vaccine | |
AUPN999096A0 (en) | Peptides, antibodies, vaccines & uses thereof | |
AU2002365924A1 (en) | Herbal immune system stimulant | |
AU2001284444A1 (en) | Preparations for oral administration | |
AU2003203002A1 (en) | Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines | |
AU2001242190A1 (en) | Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof | |
AU2002219485A1 (en) | An autologous anti-cancer vaccine | |
AU2003228863A1 (en) | Immunogenic peptides | |
AU2003264724A1 (en) | Flagellin peptides as adjuvants for vaccines | |
AU2002220924A1 (en) | Antibodies, peptides, analogs and uses thereof | |
AU2001227375A1 (en) | N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents | |
AU2001241187A1 (en) | Sustained release oral preparations | |
AU2001280120A1 (en) | Cyclic peptide derivative | |
AU2001265830A1 (en) | Solubilised protein vaccines | |
AU2001245815A1 (en) | Human immune response proteins |